Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Staphylococcus aureus alpha-hemolysin antibody - China Medical System/Trinomab Biotech

Next Previous
X
Search
Drug Profile

Anti-Staphylococcus aureus alpha-hemolysin antibody - China Medical System/Trinomab Biotech

Alternative Names: Fully Human Anti-SA Hlα Antibody - China Medical System; Fully Human Anti-SA Hlα Antibody - Trinomab; Fully Human Hlα Antibody – Trinomab

Latest Information Update: 03 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trinomab Biotech
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Hemolysin protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Staphylococcal infections

Most Recent Events

  • 18 Apr 2021 China Medical System - Trinomab Biotech (JV) acquires Anti-staphylococcus aureus alpha-hemolysin antibody from Trinomab Biotech
  • 18 Apr 2021 Preclinical trials in Staphylococcal infections in China (Parenteral)
  • 13 Nov 2019 Trinomab Biotech has patent pending for antibody against staphylococcus aureus α-hemolysin and uses thereof in World
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top